Scribd Logo
Upload

Welcome to Scribd!

  • US Prostate Cancer Drug Pipeline Analysis

    Uploaded by

    pnspharma
    7 views2 pages
    "Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009. The number of men being actively treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is on a rise in the recent years. The continuous efforts and investment being directed by the pharmaceutical companies is expected to reduce the incidence rate significantly in the next 5 year horizon. “US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Prostate Cancer Drug Pipeline Analysis” research report: • Drug Profile Overview • Alternate Names for Drug • Active Indication • Phase of Development • Mechanism of Action • Brand Name • Patent Information • Country for Clinical Trial • Owner / Originator/ Licensee/Collaborator • Administrative Route • Drug Class • ATC Codes US Prostate Cancer Drug Pipeline by Clinical Phase: • Research: 11 • Preclinical: 44 • Unknown Phase: 4 • Phase 0: 1 • Phase-I: 22 • Phase-I/II: 18 • Phase-II: 53 • Phase-II/III: 1 • Phase-III:14 • Marketed: 13"

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    "Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009. The number of men being actively treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is on a rise in the recent years. The continuous efforts and investment being directed by the pharmaceutical companies is expected to reduce the incidence rate significantly in the next 5 year horizon. “US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Prostate Cancer Drug Pipeline Analysis” research report: • Drug Profile Overview • Alternate Names for Drug • Active Indication • Phase of Development • Mechanism of Action • Brand Name • Patent Information • Country for Clinical Trial • Owner / Originator/ Licensee/Collaborator • Administrative Route • Drug Class • ATC Codes US Prostate Cancer Drug Pipeline by Clinical Phase: • Research: 11 • Preclinical: 44 • Unknown Phase: 4 • Phase 0: 1 • Phase-I: 22 • Phase-I/II: 18 • Phase-II: 53 • Phase-II/III: 1 • Phase-III:14 • Marketed: 13"

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    7 views2 pages

    US Prostate Cancer Drug Pipeline Analysis

    Uploaded by

    pnspharma
    "Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009. The number of men being actively treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is on a rise in the recent years. The continuous efforts and investment being directed by the pharmaceutical companies is expected to reduce the incidence rate significantly in the next 5 year horizon. “US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Prostate Cancer Drug Pipeline Analysis” research report: • Drug Profile Overview • Alternate Names for Drug • Active Indication • Phase of Development • Mechanism of Action • Brand Name • Patent Information • Country for Clinical Trial • Owner / Originator/ Licensee/Collaborator • Administrative Route • Drug Class • ATC Codes US Prostate Cancer Drug Pipeline by Clinical Phase: • Research: 11 • Preclinical: 44 • Unknown Phase: 4 • Phase 0: 1 • Phase-I: 22 • Phase-I/II: 18 • Phase-II: 53 • Phase-II/III: 1 • Phase-III:14 • Marketed: 13"

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    US Prostate Cancer Drug Pipeline Analysis

    Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in
    the US. According to the American Cancer Society, there were close to 242,000 new cases of
    prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from
    206,640 men diagnosed with the condition during 2009. The number of men being actively
    treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer,
    and prostatitis, is on a rise in the recent years. The continuous efforts and investment being
    directed by the pharmaceutical companies is expected to reduce the incidence rate
    significantly in the next 5 year horizon.
    US Prostate Cancer Drug Pipeline Analysis by PNS Pharma gives comprehensive insight on
    the various drugs being developed for the treatment of Prostate Cancer. Research report
    covers all the ongoing drugs being developed in various clinical development phases. This
    report enables pharmaceutical companies, collaborators and other associated stake holders to
    identify and analyze the available investment opportunity in the Prostate Cancer drug market
    based upon development process.
    For Report Sample Contact: rajesh@pnspharma.com
    Following parameters for each drug profile in development phase are covered in US Prostate
    Cancer Drug Pipeline Analysis research report:
    Drug Profile Overview
    Alternate Names for Drug
    Active Indication
    Phase of Development
    Mechanism of Action
    Brand Name
    Patent Information
    Country for Clinical Trial
    Owner / Originator/ Licensee/Collaborator
    Administrative Route
    Drug Class
    ATC Codes
    US Prostate Cancer Drug Pipeline by Clinical Phase:
    Research: 11
    Preclinical: 44
    Unknown Phase: 4
    Phase 0: 1
    Phase-I: 22
    Phase-I/II: 18
    Phase-II: 53
    Phase-II/III: 1
    Phase-III:14
    Marketed: 13
    For Report Sample Contact: rajesh@pnspharma.com
    Each Drug Profile has Tables Representing Following Information:
    Alternate Names
    Originator & Owner
    Collaborator
    Technology Provider
    Licensee
    Highest Development Phase
    Indications
    Class
    Mechanism of Action
    ATC Code
    Designated Brand Name

    You might also like